There are currently 2699 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
NCT03603730
Recruiting
Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/07/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Dyspepsia, Gastroparesis
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics), Boston, Massachusetts
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2025
Locations: Harvard/Mass General/Brigham Hospitals, Boston, Massachusetts
Conditions: Post Operative Surgical Site Infection
Register for Updates
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Recruiting
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
NCT05166161
Recruiting
The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Phenylketonuria
Register for Updates
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
NCT05734495
Recruiting
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Beth Israel Deaconness Medical, Boston, Massachusetts +1 locations
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
Comparison of Uncomplicated Candidemia Therapy Duration in Children
NCT05763251
Recruiting
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those... Read More
Gender:
ALL
Ages:
Between 120 days and 18 years
Trial Updated:
05/07/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Invasive Candidiasis
Register for Updates
Project 4: Ambulatory Biofeedback and Voice Therapy for Patients With Vocal Hyperfunction
NCT05970562
Recruiting
Vocal hyperfunction (VH) is the most commonly treated class of voice disorders by speech-language pathologists and voice therapy is the primary curative treatment. Patients and clinicians report that generalizing improved voicing into daily life is the most significant barrier to successful therapy. We will test if extending biofeedback into the patient's daily life using ambulatory voice monitoring will significantly improve generalization during therapy and if individual patient factors, like... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Voice Disorders, Vocal Fold Polyp, Vocal Nodules in Adults, Muscle Tension Dysphonia
Register for Updates
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
NCT06388707
Recruiting
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Drug Resistant Epilepsy, Epilepsy
Register for Updates
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
NCT06525259
Recruiting
The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.
Gender:
ALL
Ages:
Between 9 years and 14 years
Trial Updated:
05/07/2025
Locations: Boston Children's/Joslin Diabetes Center/Massachusetts General Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Register for Updates
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT06651580
Recruiting
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/07/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis
Register for Updates
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060
Recruiting
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lymphoma, T-Cell
Register for Updates